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mesotheliomaAbstract Background: Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that
arises from the surface cells of the pleura with a poor survival rate. Fibulin-3 is a protein biomarker
found in blood and pleural ﬂuid of patients with mesothelioma and can reliably predict the pres-
ence, or absence, of mesothelioma cancer cells. The possible role of ﬁbulin-3 in diagnosis of
MPM was studied.
Patients and methods: Sixty patients were included in the study, 30 with pleural effusions due to
MPM and another 30 with non mesothelioma malignant pleural effusion (MPE). Plasma and pleu-
ral effusion ﬁbulin-3 levels were estimated for all patients using an enzyme-linked immunosorbent
assay (ELIZA).
Results: Plasma and pleural effusion ﬁbulin-3 levels were signiﬁcantly higher in patients with
MPM (113 ± 3.7 ng/ml and 594.2 ± 65.7 ng/ml, respectively) compared to those with non mesothe-
lioma MPE (44.4 ± 7.1 ng/ml and 187.3 ± 14.5 ng/ml, respectively) (P< 0.001). Plasma and effu-
sion ﬁbulin-3 levels discriminated signiﬁcantly between patients with MPM and those with non
mesothelioma MPE, with area under receiver operating characteristic (ROC) curves of 0.98 and
0.94, respectively, at cut-off values of 54.3 ng/ml for plasma ﬁbulin-3 and 520 ng/ml for effusion ﬁb-
ulin-3, with sensitivity of 100% and 90%, speciﬁcity of 96.7% for both, positive predictive value
(PPV) of 96.8% and 96.4% and negative predictive value (NPV) of 100% and 90.6%, respectively.
Conclusion: Plasma and effusion ﬁbulin-3 levels can differentiate mesothelioma effusions from
other malignant effusions.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.
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Malignant pleural mesothelioma (MPM) is a highly aggressive
tumor that arises from the surface cells of the pleura with a
poor survival rate. Previously it was considered as a rare
tumor, MPM has become a common public health problem,
and its incidence is expected to continue to increase in the next
10 years [1].
Diagnosis of MPM is a challenging issue. Potential markers
in mesothelioma diagnosis include soluble mesothelin-related
peptides (SMRPs) and osteopontin, but no subsequent valida-
tion has been published yet [2]. Soluble mesothelin related pro-
tein, the most extensively studied blood based mesothelioma
biomarker, is limited by an overall sensitivity of 47% and
96% speciﬁcity [3]. Another ﬁnding is that a signiﬁcantly
elevated level of SMRPs was found only in epithelioid meso-
thelioma but not in sarcomatoid type, as already suggested
by Robinson and his colleagues [4]. Interestingly, Ordonez has
reported that only epithelioid mesothelioma cells are positive
for mesothelin staining, some patients with mixed-type MPM
also had elevated values of serum SMRPs. It can be speculated
that the level of serum SMRPs is correlated to the percentage
of the epithelioid component in the tumor [5].
Recently it was found that ﬁbulin-3 is a new protein bio-
marker found in blood and pleural ﬂuid of patients with meso-
thelioma and can reliably predict the presence, or absence, of
mesothelioma cancer cells. This ﬁnding could open the way
for a long sought-after screening tool for anyone exposed to
asbestos [3].
Patients and methods
The current prospective study was conducted at Pulmonary
Medicine and Cardiothoracic Surgery Departments, Zagazig
University Hospitals, during the period from July 2010 to
November 2013. Patients suspected of, or recently diagnosed
with malignant pleural effusions [6] were recruited in the study.
Pathologic diagnosis by trained pathologists was done on pleu-
ral biopsies obtained by thoracoscopy, thoracotomy, or by CT
or ultrasound-guided biopsy.
Exclusion criteria were:
1. The presence or suspicion of any concomitant infectious
disease.
2. Patients with transudative pleural effusions.
3. Previous thoracic surgery, radiotherapy, or chemotherapy
for the MPM.
4. Patient refusal to participate in the study.
After ﬁnal diagnosis was conﬁrmed pathologically, patients
were divided into 2 groups: 30 cases with conﬁrmed MPM and
30 cases with non mesothelioma malignant pleural effusionTable 1 Demographic data of the studied patients.
Parameter Mesothelioma (no = 30)
Age in years 64.4 ± 7.6
Sex: M/F 19/11
Hx. of asbestos exposure, no. (%) 23 (76.7%)
MPE; malignant pleural effusion. Hx; History. M; Male. F; Female.(MPE). After inclusion: blood and pleural ﬂuid samples were
collected from each patient where; total protein levels, lactate
dehydrogenase (LDH) levels, pleural ﬂuid glucose levels, total
and differential cell counts, in addition to levels of ﬁbulin-3
(FBLN3) were estimated. Clinical data and outcome of the
patients were also collected.
Fibulin-3 enzyme-linked immunosorbent assay
Levels of ﬁbulin-3 in plasma and pleural effusions were mea-
sured in duplicate wells and quantiﬁed in nanograms per
milliliter with the use of the human ﬁbulin-3 enzyme-linked
immunosorbent assay. Assay was done according to the
manufacturer instructions; the kit is a sandwich enzyme
immunoassay for in vitro quantitative measurement of ﬁbu-
lin-3 in human serum, plasma, urine and other biological
ﬂuids. (USCN Life Science Inc. www.uscnk.us; www.uscnk.
com).
Statistical analysis
Statistical analysis was performed with Epi Info version 7
and the SPSS version 19 statistical software package (SPSS
Inc., Chicago, IL, USA). P–value <0.05 was considered
signiﬁcant.
Results
Table 1 shows the socio- demographic data of all studied
patients. Patients with MPM were more signiﬁcantly exposed
to asbestos than those with non mesothelioma MPE with no
signiﬁcant difference regarding age and sex.
Tables 2 and 3 show no signiﬁcant differences between both
studied groups as regards pleural ﬂuid characteristics and diag-
nostic procedures used to reach the ﬁnal diagnosis. Most of the
patients in both groups were ﬁnally diagnosed through tissue
biopsy obtained by thoracoscopy (66.7% vs. 70% in MPM
vs. non mesothelioma MPE).
Table 4 shows that epithelioid type (73.3%) was the most
prevalent histopathological type among patients with MPM
followed by mixed (16.7%) then sarcomatoid (10%) types.
Table 5 shows sites of primary tumor in patients with non
mesothelioma MPE. Of these patients, 12 patients (40%) had
lung adenocarcinoma, 4 patients (13.3%) had lung squamous
cell carcinoma, 5 patients (16.7%) had breast adenocarcinoma,
3 patients (10%) had ovarian carcinoma, 2 patients (6.7%) had
gastrointestinal adenocarcinoma, 1 patient (3.3%) had lym-
phoma and 3 patients (10%) had cancer of unknown primary
site.
Table 6 shows that plasma and effusion ﬁbulin-3 levels were
signiﬁcantly higher in patients with MPM when compared
with those with non mesothelioma MPE (P< 0.001).Non mesothelioma MPE (no = 30) P-value
62.2 ± 5.9 0.22
16/14 0.60
8 (26.7%) <0.001




MPE (no = 30)
P-value
Total protein, g/dl 4.4 ± 0.2 4.2 ± 0.8 0.2
Glucose, mg/dl 85 ± 20 93 ± 16 0.1
LDH (IU/L) 560 ± 210 630 ± 199 0.2
Cytology
Positive 7 (23.3%) 8 (26.7%) 1.00
Not conclusive 23 (76.7%) 22 (73.3%)




MPE (no = 30)
P-value
Thoracoscopy 20(66.7%) 21(70%) >0.05
Surgery 2 (6.7%) 3 (10%) >0.05
Guided biopsy
(CT or US)
8 (26.6%) 6 (20%) >0.05






Table 5 Primary tumor sites in non mesothelioma malignant
pleural effusion.
Primary tumor No %
Lung adenocarcinoma 12 40
Lung squamous cell carcinoma 4 13.3
Breast adenocarcinoma 5 16.7
Ovarian adenocarcinoma 3 10
Gastro intestinal adenocarcinoma 2 6.7
Lymphoma 1 3.3
Unknown 3 10






MPE (no = 30)
P-value
Plasma ﬁbulin-3 (ng/ml) 113 ± 3.7 44.4 ± 7.1 <0.001
Eﬀusion ﬁbulin-3 (ng/ml) 594.2 ± 65.7 187.3 ± 14.5 <0.001
Table 7 Cut-off values of plasma and effusion ﬁbulin-3 (ng/
ml) for diagnosis of mesothelioma.
Parameter Cut-oﬀ values AUC 95% CI
Plasma ﬁbulin-3 (ng/ml) >54.3 0.98 (0.91–0.99)
Eﬀusion ﬁbulin-3 (ng/ml) >520 0.94 (0.85–0.98)
Plasma and pleural effusion ﬁbulin-3 levels in malignant pleural mesothelioma effusions 885Table 7 and Figs. 1 and 2, show that plasma and effusion
ﬁbulin-3 levels discriminated signiﬁcantly between patients
with MPM and those with non mesothelioma MPE, with area
under receiver operating characteristic (ROC) curves of 0.98
and 0.94, respectively, at cutoff values of 54.3 ng/ml and
520 ng/ml, with 95% CI, 0.91–0.99 and 0.85–0.98, respectively.
Table 8 and Figs. 1 and 2 show that; the sensitivity, speci-
ﬁcity, PPV and NPV at the mentioned cut-off values of plasma
and effusion ﬁbulin-3 for diagnosis of mesothelioma were
100% and 90%, 96.7% for both, 96.8% and 96.4% and
100% and 90.6%, respectively.
Discussion
Despite advances in chemotherapy, radiation therapy, and sur-
gical management for malignant pleural mesothelioma, themedian survival remains 12 months [7]. Early detection is lim-
ited by the long latency period, an inability of imaging to
detect the disease at an early stage even when it is used as a
screening strategy, and the lack of sensitive and speciﬁc
blood-based markers [8]. Moreover, in patients with undiag-
nosed pleural effusion, the ability to diagnose mesothelioma
is delayed by failure to include the disease in the differential
diagnosis and by the lack of noninvasive mesothelioma-speciﬁc
blood-based markers [9].
So, this study assessed the role of plasma and effusion ﬁb-
ulin-3, as a novel biomarker, in discriminating patients with
MPM from patients with non mesothelioma malignant pleural
effusion.
In the present study, ﬁbulin-3 was measured in plasma and
not serum to avoid the bias in results that could occur if serum
samples were used, due to the possibility of uncontrolled
thrombin cleavage, as reported in The Carotene and Retinol
Efﬁcacy Trial (CARET) [30]. Whereas, in this trial the data
suggest that plasma, not serum, should be used for ﬁbulin mea-
surement, as this validation study with serum samples obtained
from CARET participants failed to discriminate between
patients with and those without malignant pleural mesotheli-
oma (AUC, 0.56 [University of California, Los Angeles] and
0.52 [New York University]), even in fresh specimens collected
simultaneously and stored for less than 2 years, the serum lev-
els were signiﬁcantly lower than the plasma levels. This could
be explained by the fact that analysis of the structure of ﬁbu-
lin-3 revealed at least two thrombin cleavage sites [31] similar
to those of ﬁbulin-2 [32]. So Pass et al. [9] performed another
blinded validation study using plasma samples which showed
excellent discrimination between the controls and the patients
with mesothelioma (AUC, 0.87).
This study included 60 patients who were divided according
to histopathological examination into 30 cases with conﬁrmed
MPM and 30 cases with non mesothelioma MPE. Male sex
(63.3%) was more predominant than female (36.7%) in
patients with MPM (Table 1). Male predominance could be
related to their occupational exposure to asbestos dust more
than females. This is in agreement with Sterman et al. [6]. Also
Table 1 shows that patients with MPM had a signiﬁcant his-
tory of exposure to asbestos (76%). This in accordance with
Sterman and Albelda [10] who stated that inhalational exposure
ROC curve for Plasma Fibulin-3 levels( ng/ml)















 Criterion : >54.3
Figure 1 Receiver Operating Characteristic (ROC) curve for
plasma ﬁbulin-3 levels in diagnosis of malignant pleural
mesothelioma.
ROC curve for pleural fluid fibulin-3( ng/ml)















 Criterion : >520
Figure 2 Receiver Operating Characteristic (ROC) curve for
pleural ﬂuid ﬁbulin-3 levels in diagnosis of malignant pleural
mesothelioma.
886 Alaa eldin M. Elgazzar et al.to asbestos has been clearly established as the predominant
cause of malignant mesothelioma in humans. The lifetime risk
of developing mesothelioma among asbestos workers is
thought to be as high as 8–13%. There is typically a long
latency period of approximately 30–40 years from the time of
asbestos exposure to the development of mesothelioma. This
explains the older age of MPM patients in the current study
(64.4 ± 7.6).
The current study showed that; most of the patients in both
groups were ﬁnally diagnosed through tissue biopsy obtained
by thoracoscopy (66.7% vs. 70% in MPM vs. non mesotheli-
oma MPE Table 3). This coincides with Broaddus and Robin-
son [11], who reported that the preferred technique forTable 8 Sensitivity, speciﬁcity, PPV and NPV at cut-off value
mesothelioma.
Parameter Sensitivity (%)
Plasma ﬁbulin-3 (>54.3 ng/ml) 100
Eﬀusion ﬁbulin-3 (>520 ng/ml) 90surgical biopsy is via pleuroscopy. Not only does pleuroscopy
has the advantage of obtaining large samples, but also, it per-
mits the drainage of effusions and releasing of the trapped
lung. In addition, if the lung is not trapped, talc can be insuf-
ﬂated at the end of the procedure to achieve a pleurodesis.
Table 4 shows that epithelioid type (73.3%) was the most
prevalent histopathological type among patients with MPM
followed by mixed (16.7%) then sarcomatoid (10%) types.
these results are in agreement with other studies reporting
highest frequency for epithelioid type and lowest for sarcoma-
toid type [12–14].
The results of this study suggest that levels of ﬁbulin-3 in
plasma and effusions may help in conﬁrmation of the diagno-
sis of malignant pleural mesothelioma. As shown in Table 6
plasma and effusion ﬁbulin-3 levels were signiﬁcantly higher
in patients with MPM (113 ± 3.7 and 594.2 ± 65.7, respec-
tively) vs. non mesothelioma MPE (44.4 ± 7.1 and 187.3 ±
14.5, respectively) (P< 0.001). Also, the speciﬁcity and sensi-
tivity of ﬁbulin-3 in discriminating between patients with non
mesothelioma malignant effusions, and patients with mesothe-
lioma are superior to those of some other published markers.
In addition, high levels of ﬁbulin-3 in effusions have a high
positive predictive value for the presence of mesothelioma.
All those, are illustrated in Tables 7 and 8 and Figs. 1 and 2
which showed that plasma and effusion ﬁbulin-3 levels dis-
criminated signiﬁcantly between patients with MPM and those
with non mesothelioma MPE, with area under receiver operat-
ing characteristic (ROC) curves of (0.98 and 0.94), respectively,
at cutoff values of 54.3 ng/ml for plasma and 520 ng/ml for
pleural effusion, the 95% CI, 0.91–0.99 and 0.85–0.98, with
sensitivity of 100% and 90%, speciﬁcity of 96.7% for both,
positive predictive value (PPV) of 96.8% and 96.4% and neg-
ative predictive value (NPV) of 100% and 90.6%, respectively.
These results are in accordance with Pass et al. [9] who mea-
sured ﬁbulin-3 levels in plasma (from 92 patients with meso-
thelioma, 136 asbestos-exposed persons without cancer, 93
patients with effusions not due to mesothelioma, and 43
healthy controls), and in pleural effusions (from 74 patients
with mesothelioma, 39 with benign effusions, and 54 with
malignant effusions not due to mesothelioma), or both. And
found that Plasma ﬁbulin-3 levels were signiﬁcantly higher in
patients with pleural mesothelioma (105 ± 7 ng/ml in the
Detroit cohort and 113 ± 8 ng/ml in the New York cohort)
than in asbestos-exposed persons without mesothelioma
(14 ± 1 ng/ml and 24 ± 1 ng/ml, respectively; P< 0.001).
Effusion ﬁbulin-3 levels were signiﬁcantly higher in patients
with pleural mesothelioma (694 ± 37 ng/ml in the Detroit
cohort and 636 ± 92 ng/ml in the New York cohort) than in
patients with effusions not due to mesothelioma (212 ± 25
and 151 ± 23 ng/ml, respectively; P< 0.001). In an overall
comparison of patients with and those without mesothelioma,
the receiver-operating-characteristic curve for plasma ﬁbulin-3s of plasma and effusion ﬁbulin-3 (ng/ml) for diagnosis of
Speciﬁcity (%) PPV NPV
96.7 96.8 100
96.7 96.4 90.6
Plasma and pleural effusion ﬁbulin-3 levels in malignant pleural mesothelioma effusions 887levels had a sensitivity of 96.7% and a speciﬁcity of 95.5% at a
cutoff value of 52.8 ng of ﬁbulin-3 per milliliter [9].
Fibulin-3 is a member of the extracellular glycoprotein
ﬁbulin family encoded by the gene epidermal growth factor–
containing ﬁbulin-like extracellular matrix protein 1
(EFEMP1) on chromosome 2p16 [15]. Gene expression is
low in normal tissues, with the highest expression in the thy-
roid [16]. Fibulin-3 is expressed in condensing mesenchyme,
giving rise to bony and cartilaginous structures [17]. It medi-
ates cell-to-cell and cell-to- matrix communication, it is inver-
sely related to cell growth, and has variable angiogenic effects
[18,19]. Inactivation of EFEMP1 due to DNA hypermethyla-
tion has been reported in lung [20,21], prostate [22], colorectal
[23], breast [24], nasopharyngeal [25] and hepatocellular [26]
carcinomas. In contrast, ﬁbulin-3 is up regulated in pancreatic
adenocarcinoma metastases [27], and there are conﬂicting
opinions about whether the elevated expression of ﬁbulin-3
enhances or suppresses invasion of glioblastomas [28,29].
In conclusion, plasma and effusion ﬁbulin-3 levels can
differentiate mesothelioma effusions from other malignant
effusions.Conﬂict of interest
None declared.References
[1] B.W. Robinson, A.W. Musk, R.A. Lake, Malignant
mesothelioma, Lancet 366 (2005) 397–408.
[2] A. Scherpereel, B. Grigoriu, M. Conti, et al, Soluble
mesothelin-related peptides in the diagnosis of malignant
pleural mesothelioma, Am. J. Respir. Crit. Care Med. 173 (10)
(2006) 1155–1160.
[3] K. Hollevoet, J.B. Reitsma, J. Creaney, et al, Plasma mesothelin
for diagnosing malignant pleural mesothelioma: an individual
patient data meta-analysis, J. Clin. Oncol. 30 (2012) 1541–1549.
[4] B.W. Robinson, J. Creaney, R. Lake, et al, Mesothelin-family
proteins and diagnosis of mesothelioma, Lancet 362 (2003)
1612–1616.
[5] N.G. Ordonez, The diagnostic utility of immunohistochemistry
in distinguishing between mesothelioma and renal cell
carcinoma: a comparative study, Hum. Pathol. 35 (2004) 697–
710.
[6] D.H. Sterman, L.A. Litzky, S.M. Albelda, Malignant
mesothelioma and other primary pleural tumors, ﬁfth ed., in:
A.P. Fishman, J.A. Elias, J.A. Fishman, M.A. Grippi, R.M.
Senior, A.I. Pack (Eds.), Fishman’s Pulmonary Diseases and
Disorders, Mc Graw-Gill, New York, 2008, p. 1435 (chapter 92).
[7] N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, et al, Phase III
study of pemetrexed in combination with cisplatin versus
cisplatin alone in patients with malignant pleural
mesothelioma, J. Clin. Oncol. 21 (2003) 2636–2644.
[8] H.I. Pass, M. Carbone, Current status of screening for
malignant pleural mesothelioma, Semin. Thorac. Cardiovasc.
Surg. 21 (2009) 97–104.
[9] H.I. Pass, S.M. Levin, M.R. Harbut, et al, Fibulin-3 as a blood
and effusion biomarker for pleural mesothelioma, N. Engl. J.
Med. 367 (15) (2012) 1417–1427.
[10] D.H. Sterman, S.M. Albelda, Advances in the diagnosis,
evaluation and management of malignant pleural
mesothelioma, Respirology 10 (2005) 266–283.
[11] V.C. Broaddus, B.W.S. Robinson, Tumors of the pleura, ﬁfth
ed., in: R.J. Mason (Ed.), Murray and Nadel’s Textbook ofRespiratory Medicine, Saunders (Elsevier Inc), 2010, p. 1792
(vol. 2; chapter 73).
[12] T.W. Beer, P. Shepherd, N.C. Pullinger, Immunostaining is
related to prognosis in malignant mesothelioma, Histopathology
38 (2001) 515–541.
[13] J.R. Testa, H.I. Pass, M. Carbone, Molecular biology of
mesothelioma, sixth ed., in: V.T. DeVita, S. Hellman, S.A.
Rosenberg (Eds.), Cancer: Principles and Practice of Oncology,
Lippincott, Philadelphia, 2000, pp. 1937–1942.
[14] C. Boutin, F. Rey, J. Gouvernet, et al, Thoracoscopy in pleural
malignant mesothelioma: a prospective study of 188 consecutive
patients, Cancer 72 (1993) 394–404.
[15] Y. Zhang, L.Y. Marmorstein, Focus on molecules: ﬁbulin-3
(EFEMP1), Exp. Eye Res. 90 (2010) 374–375.
[16] N. Kobayashi, G. Kostka, J.H. Garbe, et al, A comparative
analysis of the ﬁbulin protein family: biochemical
characterization, binding interactions, and tissue localization,
J. Biol. Chem. 282 (2007) 11805–11816.
[17] R.M. Moore, R.W. Redline, D. Kumar, et al, Differential
expression of ﬁbulin family proteins in the paracervical weak
zone and other areas of human fetal membranes, Placenta 30
(2009) 335–341.
[18] F. Segade, Molecular evolution of the ﬁbulins: implications on
the functionality of the elastic ﬁbulins, Gene 464 (2010) 17–31.
[19] A.R. Albig, J.R. Neil, W.P. Schiemann, Fibulins 3 and 5
antagonize tumor angiogenesis in vivo, Cancer Res. 66 (2006)
2621–2629.
[20] E.J. Kim, S.Y. Lee, M.K. Woo, et al, Fibulin-3 promoter
methylation alters the invasive behavior of non-small cell lung
cancer cell lines via MMP-7 and MMP-2 regulation, Int. J.
Oncol. 40 (2012) 402–408.
[21] W. Yue, S. Dacic, Q. Sun, et al, Frequent inactivation of
RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter
hypermethylation, Clin. Cancer Res. 13 (2007) 4336–4344.
[22] Y.J. Kim, H.Y. Yoon, S.K. Kim, et al, EFEMP1 as a novel
DNA methylation marker for prostate cancer: array-based
DNA methylation and expression proﬁling, Clin. Cancer Res.
17 (2011) 4523–4530.
[23] J.D. Tong, N.L. Jiao, Y.X. Wang, et al, Downregulation of
ﬁbulin-3 gene by promoter methylation in colorectal cancer
predicts adverse prognosis, Neoplasma 58 (2011) 441–448.
[24] A. Sadr-Nabavi, J. Ramser, J. Volkmann, et al, Decreased
expression of angiogenesis antagonist EFEMP1 in sporadic
breast cancer is caused by aberrant promoter methylation and
points to an impact of EFEMP1 as molecular biomarker, Int. J.
Cancer 124 (2009) 1727–1735.
[25] C.F. Hwang, C.Y. Chien, S.C. Huang, et al, Fibulin-3 is
associated with tumour pro gression and a poor prognosis in
nasopharyngeal carcinomas and inhibits cell migration and
invasion via suppressed AKT activity, J. Pathol. 222 (2010) 367–
379.
[26] S. Nomoto, M. Kanda, Y. Okamura, et al, Epidermal growth
factor-containing ﬁbulin-like extracellular matrix protein 1,
EFEMP1, a novel tumor-suppressor gene detected in
hepatocellular carcinoma using double combination array
analysis, Ann. Surg. Oncol. 17 (2010) 923–932.
[27] H. Seeliger, P. Camaj, I. Ischenko, et al, EFEMP1 expression
promotes in vivo tumor growth in human pancreatic
adenocarcinoma, Mol. Cancer Res. 7 (2009) 189–198.
[28] B. Hu, K.K. Thirtamara-Rajamani, H. Sim, et al, Fibulin-3 is
uniquely up- regulated in malignant gliomas and promotes
tumor cell motility and invasion, Mol. Cancer Res. 7 (2009)
1756–1770.
[29] Y. Hu, P.D. Pioli, E. Siegel, et al, EFEMP1 suppresses
malignant glioma growth and exerts its action within the
tumor extracellular compartment, Mol. Cancer 10 (2011) 123.
[30] S. Barnhart, J. Keogh, M.R. Cullen, et al, The CARET
asbestos-exposed cohort: baseline characteristics and
888 Alaa eldin M. Elgazzar et al.comparison to other asbestos-exposed cohorts, Am. J. Ind. Med.
32 (1997) 573–581.
[31] H. Tran, M. Mattei, S. Godyna, W.S. Argraves, Human ﬁbulin-
1D: molecular cloning, expression and similarity with S1–5
protein, a new member of the ﬁbulin gene family, Matrix Biol.
15 (1997) 479–493.[32] T. Sasaki, K. Mann, G. Murphy, et al, Different susceptibilities
of ﬁbulin-1 and ﬁbulin-2 to cleavage by matrix
metalloproteinases and other tissue proteases, Eur. J. Biochem.
240 (1996) 427–434.
